CryoPort, Inc. (NASDAQ:CYRX) Shares Bought by Readystate Asset Management LP

Readystate Asset Management LP increased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 91.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 500,344 shares of the company's stock after buying an additional 239,153 shares during the quarter. Readystate Asset Management LP owned about 1.00% of CryoPort worth $3,042,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CYRX. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after buying an additional 2,120 shares during the last quarter. Lazard Asset Management LLC acquired a new position in shares of CryoPort in the fourth quarter valued at about $51,000. SBI Securities Co. Ltd. increased its holdings in shares of CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after purchasing an additional 10,975 shares during the period. Quarry LP acquired a new position in shares of CryoPort in the fourth quarter valued at about $69,000. Finally, CWM LLC increased its holdings in shares of CryoPort by 1,437.0% in the first quarter. CWM LLC now owns 11,328 shares of the company's stock valued at $69,000 after purchasing an additional 10,591 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Stock Performance

CYRX stock traded down $0.13 during midday trading on Friday, hitting $7.85. 665,310 shares of the stock traded hands, compared to its average volume of 455,408. The firm has a market cap of $393.60 million, a P/E ratio of -3.35 and a beta of 1.89. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.56 and a quick ratio of 5.24. The stock's fifty day simple moving average is $6.92 and its 200-day simple moving average is $6.61. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $9.66.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. On average, analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Roth Mkm reissued a "buy" rating and issued a $15.00 price objective on shares of CryoPort in a report on Tuesday, April 1st. Morgan Stanley decreased their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Stephens started coverage on shares of CryoPort in a research report on Tuesday. They set an "overweight" rating and a $13.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of CryoPort in a research report on Thursday, May 8th. Finally, BTIG Research decreased their target price on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $11.11.

Insider Activity at CryoPort

In other CryoPort news, insider Edward J. Zecchini sold 51,500 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total transaction of $352,260.00. Following the completion of the transaction, the insider directly owned 90,411 shares in the company, valued at approximately $618,411.24. This represents a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Hariri sold 12,500 shares of the company's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total transaction of $76,250.00. Following the transaction, the director owned 8,061 shares of the company's stock, valued at $49,172.10. This represents a 60.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 490,447 shares of company stock valued at $3,337,198. Insiders own 10.00% of the company's stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.